References
- Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. N Engl J Med. 2002;346(4):257–270.
- Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018 21;19(1):17.
- Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–349.
- Dodick DW. Migraine. Lancet. 2018;391(10127):1315–1330.
- Lionetto L, Capi M, Curto M, et al. Rimegepant. Drugs Future. 2019;44(8):1–8.
- Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol. 2007;254:705–712.
- Hougaard A, Tfelt-Hansen P. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists. Expert Opin Drug Metab Toxicol. 2015;11(9):1409–1418.
- Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Joint. 1994;34:394–399. Wolff Award Presentation Headache.
- Haanes KA, Edvinsson L. Pathophysiological mechanisms in migraine and the identification of new therapeutic targets. CNS Drugs. 2019 Jun;33(6):525–537.
- Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018 11;91(24):e2222–e2232.
- Edvinsson L, Haanes KA, Warfvinge K. Does inflammation have a role in migraine? Nat Rev Neurol. 2019 Aug;15(8):483–490.
- Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018 Jun;14(6):338–350.
- Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990 Aug;28(2):183–187.
- Ramachandran R. Neurogenic inflammation and its role in migraine. Semin Immunopathol. 2018 May;40(3):301–314.
- Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555–567.
- Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019;20(1):37.
- Holland PR, Goadsby PJ. Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics. 2018 Apr;15(2):304–312.
- Taylor FR. CGRP, amylin, immunology, and headache medicine. Headache. 2019;59(1):131–150.
- Moore E, Burgey CS, Fraley M, et al. Characterization of ubrogepant: a potent and selective antagonist of the human calcitonin gene-related peptide receptor (P4.10-021). Neurology. 2019 Apr;92(15 Supplement):P4.10–021.
- Goadsby PJ, Tepper SJ, Watkins PB, et al. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: randomized, placebo-controlled trial in healthy adults. Cephalalgia. 2019 Dec;39(14):1753–1761.
- Allergan. A pharmacokinetic study of MK-1602 in the treatment of acute migraine (MK-1602-007. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2020 Jan 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT01657370?term=NCT01657370NLMIdentifier: NCT01657370
- Li CC, Dockendorf M, Kowalski K, et al. Population PK analyses of ubrogepant (MK-1602), a CGRP receptor antagonist: enriching in-clinic plasma PK sampling with outpatient dried blood spot sampling. J Clin Pharmacol. 2018 Mar;58(3):294–303.
- Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016 Aug;36(9):887–898.
- Allergan. Efficacy, safety, and tolerability study of oral ubrogepant in the acute treatment of migraine (ACHIEVE I). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2020 Jan 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT01657370?term=NCT01657370 NLM Identifier: NCT02828020
- Allergan. Efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine (ACHIEVE II). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2020 Jan 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02867709?term=NCT02867709 NLM Identifier: NCT02867709
- Allergan. An extension study to evaluate the long-term safety and tolerability of ubrogepant in the treatment of migraine. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2020 Jan 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02873221?term=NCT02873221 NLM Identifier: NCT02873221